Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous iron formulations and kidney injury markers in chronic kidney disease
2010-020452-64Phase 4Completed
- Sponsor
- Hull University Teaching Hospitals
- Start
- Oct 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iron sucrose and ferric derisomaltose in iron deficiency anemia (IDA) (3 arms), sponsored by Hull University Teaching Hospitals. Primary endpoints: Time course of markers of renal injury, NGAL in serum and urine and 2 more. Started Oct 2010; status: completed.
02
Drugs
iron sucroseferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2010-020452-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020452-64.